According to the latest version of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, depending on the PD-L1 expression status, they can be prescribed as first-line or subsequent treatment with or without chemoradiotherapy or as part of neoadjuvant and adjuvant therapy for squamous and non-squamous NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.